JP2013514979A - メサラミン坐剤 - Google Patents

メサラミン坐剤 Download PDF

Info

Publication number
JP2013514979A
JP2013514979A JP2012544851A JP2012544851A JP2013514979A JP 2013514979 A JP2013514979 A JP 2013514979A JP 2012544851 A JP2012544851 A JP 2012544851A JP 2012544851 A JP2012544851 A JP 2012544851A JP 2013514979 A JP2013514979 A JP 2013514979A
Authority
JP
Japan
Prior art keywords
mesalamine
suppository
dissolution
rectal suppository
measured
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012544851A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013514979A5 (https=
Inventor
パウエル，デイヴィッド
デュムラン，イーヴ
ゴーティエ，カール
モロー，ユーグ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aptalis Pharma Canada ULC
Original Assignee
Aptalis Pharma Canada ULC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43901620&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2013514979(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aptalis Pharma Canada ULC filed Critical Aptalis Pharma Canada ULC
Publication of JP2013514979A publication Critical patent/JP2013514979A/ja
Publication of JP2013514979A5 publication Critical patent/JP2013514979A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2012544851A 2009-12-16 2010-12-16 メサラミン坐剤 Pending JP2013514979A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/639,645 2009-12-16
US12/639,645 US8436051B2 (en) 2007-06-08 2009-12-16 Mesalamine suppository
PCT/US2010/060849 WO2011084638A2 (en) 2009-12-16 2010-12-16 Mesalamine suppository

Publications (2)

Publication Number Publication Date
JP2013514979A true JP2013514979A (ja) 2013-05-02
JP2013514979A5 JP2013514979A5 (https=) 2014-02-13

Family

ID=43901620

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012544851A Pending JP2013514979A (ja) 2009-12-16 2010-12-16 メサラミン坐剤

Country Status (14)

Country Link
US (2) US8436051B2 (https=)
EP (1) EP2512443A2 (https=)
JP (1) JP2013514979A (https=)
KR (1) KR20120104604A (https=)
CN (1) CN102970971A (https=)
AU (1) AU2010339837A1 (https=)
CA (2) CA2690450A1 (https=)
CL (1) CL2012001636A1 (https=)
IL (1) IL220397A0 (https=)
MX (1) MX2012006902A (https=)
RU (1) RU2012125186A (https=)
SG (1) SG181169A1 (https=)
WO (1) WO2011084638A2 (https=)
ZA (1) ZA201204422B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013537886A (ja) * 2010-09-10 2013-10-07 ファーマゼル ゲーエムベーハー 結晶性５−アミノサリチル酸の製造方法
JP2023501948A (ja) * 2019-10-31 2023-01-20 アール．ピー．シェーラー テクノロジーズ，エルエルシー 坐剤カプセル

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8436051B2 (en) 2007-06-08 2013-05-07 Aptalis Pharma Canada Inc. Mesalamine suppository
ATE532886T1 (de) 2008-09-19 2011-11-15 Oerlikon Trading Ag Verfahren zum herstellen von metalloxidschichten durch funkenverdampfung
WO2013059768A1 (en) * 2011-10-20 2013-04-25 Aptalis Pharma U.S., Inc. Therapeutic agents for treating gastrointestinal disorders associated with inflammation of the gastrointestinal tract
CN103622974B (zh) * 2013-12-05 2016-04-20 武汉武药科技有限公司 一种含美沙拉嗪和n-乙酰半胱氨酸的复方栓剂及其制备方法
US20160175271A1 (en) * 2014-12-19 2016-06-23 Gavis Pharmaceuticals Rectal suppository for ulcerative colitis
US10098898B1 (en) 2017-12-04 2018-10-16 Handa Pharmaceuticals, Llc Release stable mesalamine dosage forms
KR20250042058A (ko) 2023-09-19 2025-03-26 한양대학교 산학협력단 염증성 장 질환 치료용 약학적 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090022793A1 (en) * 2007-06-08 2009-01-22 Axcan Pharma Inc. Mesalamine suppository
US20090264386A1 (en) * 2007-06-08 2009-10-22 Axcan Pharma Inc. Mesalamine suppository

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3689514A (en) 1969-05-21 1972-09-05 Schlueter Edelfett Suppository vehicle and process of making same
US4211777A (en) 1977-11-25 1980-07-08 Fisons Limited Compositions comprising a compound having sodium cromoglycate activity and aminosalicylic acid
US4298595A (en) 1978-12-20 1981-11-03 Dynapol Pharmaceutical preparations containing a polymeric agent for releasing 5-aminosalicylic acid or its salts into the gastrointestinal tract
US4374932A (en) 1981-06-08 1983-02-22 G. D. Searle & Co. 5-ASA Drug delivery system
DE3151196A1 (de) 1981-12-23 1983-06-30 Kurt Heinz Prof. Dr. 7800 Freiburg Bauer Verfahren zur herstellung von gut loeslichen 5-aminosalicylsaeure-arzneimittelzubereitungen
JPH0816051B2 (ja) 1988-12-07 1996-02-21 エスエス製薬株式会社 徐放性坐剤
US5629012A (en) 1991-06-17 1997-05-13 Farmaceutisk Laboratorium Ferring A/S Process for producing suppositories by compression and suppositories obtained by the process
GB9201857D0 (en) 1992-01-29 1992-03-18 Smithkline Beecham Plc Novel compound
US5389375A (en) 1993-05-21 1995-02-14 University Of Mississippi Stable suppository formulations effecting bioavailability of Δ9 -thc
DK66493D0 (da) 1993-06-08 1993-06-08 Ferring A S Praeparater, isaer til brug ved behandling af inflammatoriske tarmsygdomme eller til at opnaa forbedret saarheling
DE69625918T2 (de) 1995-09-07 2003-08-07 Taisho Pharmaceutical Co., Ltd. Lang wirksames mittel zur rektalen verabreichung
JPH09323934A (ja) 1996-05-31 1997-12-16 Kanebo Ltd 保存安定性の改善された坐剤
AR012304A1 (es) 1997-04-01 2000-10-18 Borody Thomas J Composiciones y metodos para el tratamiento de enfermedades intestinales inflamatorias y el uso de dicha composicion para preparar medicamentos paradichos tratamientos.
US7341741B1 (en) 1997-09-26 2008-03-11 Jean-Pierre Sachetto Pharmaceutical composition for the treatment of inflammatory bowel disease
ID21009A (id) 1997-10-08 1999-04-08 Taisho Pharmaceutical Co Ltd Komposisi untuk supositori
US6326364B1 (en) 1999-02-08 2001-12-04 Cedars-Sinai Medical Center Use of 5-aminosalicylates as antimicrobial agents
US6610674B1 (en) 1999-09-28 2003-08-26 University Of Pennsylvania Method of treating inflammatory conditions with progesterone analogs
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US20020037855A1 (en) 2000-05-05 2002-03-28 Fritz Stanislaus Stabilized medicament containing cysteinyl derivatives
WO2002018324A2 (en) 2000-08-29 2002-03-07 Nobex Corporation Immunoregulatory compounds, derivatives thereof and their use
WO2004017921A2 (en) 2002-08-23 2004-03-04 Zymogenetics, Inc. Method for treating inflammatory bowel disease
US7312243B1 (en) 2003-08-29 2007-12-25 Jay Pravda Materials and methods for treatment of gastrointestinal disorders
US7825106B2 (en) 2003-09-03 2010-11-02 Agi Therapeutics Ltd. Modified release formulations and methods of treating inflammatory bowel disease
WO2005072113A2 (en) 2004-01-20 2005-08-11 Harty Richard F Compositions and methods of treatment for inflammatory diseases
WO2005115075A2 (en) 2004-05-27 2005-12-08 Antibe Therapeutics Inc. Salt of 4- or 5- aminosalicylic acid
CZ2004945A3 (cs) 2004-09-08 2006-01-11 Pliva - Lachema A. S. Farmaceutická kompozice pro rektální nebo vaginální podání, zpusob její prípravy a tato kompozice pro pouzití jako lécivo
EP2444071A1 (en) 2004-09-27 2012-04-25 Sigmoid Pharma Limited Minicapsule formulations
US7250445B1 (en) 2005-01-14 2007-07-31 Ehrenpreis Eli D Anti-oxidant suppository for treating radiation proctopathy and other anorectal disorders
US8921344B2 (en) 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
CA2644889A1 (en) 2006-03-07 2007-09-13 Combinatorx, Incorporated Compositions and methods for the treatment of immunoinflammatory disorders
US20070240236A1 (en) 2006-04-05 2007-10-11 Oklahoma Medical Research Foundation O-glycans in the treatment of inflammatory bowel disease and cancers
US20070254050A1 (en) 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome
SG195538A1 (en) 2006-05-01 2013-12-30 Napo Pharmaceuticals Inc Method for treatment of constipation-predominant irritable bowel syndrome
WO2008031013A1 (en) 2006-09-08 2008-03-13 Gene Logic Inc. Method for treating inflammatory diseases of the digestive tract
US8436051B2 (en) 2007-06-08 2013-05-07 Aptalis Pharma Canada Inc. Mesalamine suppository

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090022793A1 (en) * 2007-06-08 2009-01-22 Axcan Pharma Inc. Mesalamine suppository
US20090264386A1 (en) * 2007-06-08 2009-10-22 Axcan Pharma Inc. Mesalamine suppository

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6014047978; 杉山雄一、山本恵司: 総合製剤学 , 20000403, 第４３５〜４３６頁, 株式会社南山堂 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013537886A (ja) * 2010-09-10 2013-10-07 ファーマゼル ゲーエムベーハー 結晶性５−アミノサリチル酸の製造方法
JP2023501948A (ja) * 2019-10-31 2023-01-20 アール．ピー．シェーラー テクノロジーズ，エルエルシー 坐剤カプセル

Also Published As

Publication number Publication date
US20100105639A1 (en) 2010-04-29
EP2512443A2 (en) 2012-10-24
SG181169A1 (en) 2012-07-30
WO2011084638A2 (en) 2011-07-14
AU2010339837A1 (en) 2012-06-28
US8436051B2 (en) 2013-05-07
MX2012006902A (es) 2012-10-05
US9884018B2 (en) 2018-02-06
WO2011084638A3 (en) 2012-04-05
IL220397A0 (en) 2012-08-30
ZA201204422B (en) 2013-08-28
CL2012001636A1 (es) 2012-10-12
CA2784772A1 (en) 2011-07-14
CN102970971A (zh) 2013-03-13
CA2690450A1 (en) 2011-06-16
KR20120104604A (ko) 2012-09-21
US20130231310A1 (en) 2013-09-05
RU2012125186A (ru) 2014-01-27

Similar Documents

Publication Publication Date Title
JP2013514979A (ja) メサラミン坐剤
KR101292573B1 (ko) 젤리 조성물
JP6359517B2 (ja) ω−３脂肪酸エステル組成物
CA2974495C (en) .omega.-3 fatty acid self-emulsifying composition
AU2009309237B2 (en) Fatty acids for use as a medicament
CN103957888B (zh) 用于将药物沿胃肠道靶向释放的pH依赖性载体、其组合物及其制备和应用
US12186346B2 (en) Topical composition comprised of cod liver oil for treating wounds and skin disorders
US8217083B2 (en) Mesalamine suppository
US7541384B2 (en) Mesalamine suppository
JP2023518822A (ja) ｐＨ依存的再構築が可能な医薬キャリア、その製造方法及び使用方法
JP2015521657A (ja) Ｓ−アリル−ｌ−システインを有効成分として含む大腸炎予防または治療用組成物、およびこれを含む医薬製剤
WO2013035113A1 (en) Coated suppositories
JP2017509630A (ja) プロゲステロン製剤
KR20050010464A (ko) 치료제
CN110337300B (zh) 脂质组合
US12396946B1 (en) Methods of treating gastrointestinal diseases and disorders
US20160175329A1 (en) Mesalamine suppository
JP2018519345A (ja) 直腸の炎症性変化の治療用医薬製剤
US20160175270A1 (en) Rectal suppository for ulcerative colitis
CN105434333B (zh) 美索舒利栓剂及其制备方法和用途
RU2498810C1 (ru) Средство с 5-аминосалициловой кислотой кверцетином и экстрактом прополиса, обладающее антиоксидантной активностью
US20150202149A1 (en) Pharmaceutical compositions of mesalamine suppositories
US20160175271A1 (en) Rectal suppository for ulcerative colitis
CZ2011541A3 (cs) Kompozice pro lécbu zánetlivých onemocnení

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131213

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20141010

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141118

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150414